EULAR 2022: Use Of Glucocorticoids In Rheumatic Disease: Weighing The Balance of Benefits and Harms

New data released at EULAR suggest a favourable balance in the long term

—

Low-dose glucocorticoid therapy is widely used in rheumatoid arthritis (RA), but they cause a wide range of adverse side effects which are of concern both to patients and clinicians, and the true balance of benefit and harm is still unknown. Several groups are attempting to elucidate the long-term picture for the use of glucocorticoids in rheumatic diseases, and several interesting findings were presented at the 2022 EULAR Congress.

EULAR 2022: Patient Involvement and Empowerment: Coping with Rheumatic Diseases

Projects benefit from inclusion of the patient voice

—

Having a rheumatic and musculoskeletal Disease (RMD) has an impact on daily activities, work, relationships, and quality of life. Patients may also feel a sense of invalidation. EULAR – The European Alliance of Associations for Rheumatology – has made efforts to raise awareness for the burden imposed by RMDs and promote the best quality of care, including recognition and psychosocial support. However, it is unclear how frequent and severe the problem remains nowadays. Several groups presenting findings at the 2022 EULAR Congress on patient empowerment and research aimed at helping people cope with living with an RMD.

EULAR 75th Anniversary Timeline

To mark its 75th Anniversary, EULAR has documented its history and contribution to rheumatology in an anniversary timeline. Click on the link below - this will lead you to an interactive timeline where you can scroll through the different stages of EULAR's journey to date using the arrows on the left and right sides of the screen.

EULAR Announces Measures to Support Ukraine

EULAR has taken a series of decisions in view of Russia’s government attack on Ukraine

—

The European Alliance of Associations for Rheumatology, EULAR, strongly dissents Russia’s government attack on Ukraine, in violation of Ukraine’s sovereignty, territorial integrity, independence, and the welfare of its residents. As hospitals are being attacked and access to medical aid is interrupted, EULAR wants to respond to this humanitarian crisis and particularly support the Ukrainian people with rheumatic and musculoskeletal diseases (RMDs), who need urgent treatment and assistance.

EULAR is looking for the next Executive Director!

EULAR is looking for a committed personality to succeed the current holder of the position as Executive Director, and continue to support and shape EULAR in its aims to reduce the imapct of RMDs on the individual and society. 
 

Interested?

Please send your CV, reference letters and letter of motivation in one file to kaderselektion@bdo.ch.

EULAR Press Releases

The latest:

• NEW: EULAR Publication on Therapeutic Drug Monitoring in People with Rheumatic Disease

• Announcement: EULAR COVID-19 Registry to close

• EULAR Announces Measures to Support Ukraine

• Updated: COVID-19 Vaccination

New: EULAR COVID-19 Repositories for patients and clinicians

Find EULAR guidances and useful resources on COVID-19 outbreak to obtain the best possible recommendations and support:

• RMDs and COVID-19 repository for Clinicians
• RMDs and COVID-19 repository for Patients

EULAR Recommendations

Read the latest:

• EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
• EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis

EULAR COVID-19 Registries for rheumatologists and other clinicians

To report cases of COVID-19, as well as vaccination, in patients with RMDs